Resonance Health Ltd (ASX: RHT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Resonance Health Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$33.52 million
P/E Ratio
100.00
Dividend Yield
0.00%
Shares Outstanding
446.89 million
Earnings per share
-0.002
Dividend per share
N/A
Year To Date Return
25.00%
Earnings Yield
1.00%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Resonance Health Ltd (ASX: RHT)
Latest News
Healthcare Shares
Here's why the Resonance Health (ASX:RHT) share price is rocketing 36% today
Share Market News
Here's why the Resonance Health (ASX:RHT) share price rocketed
Share Market News
Resonance Health (ASX:RHT) announces its share price is in trading halt
Share Market News
The Resonance Health (ASX:RHT) share price has rocketed up 9% today. Here's why.
Share Market News
Why the Resonance Health (ASX:RHT) share price is shooting 39% higher today
Share Gainers
Why Afterpay, Creso Pharma, Healius, & Resonance Health shares are storming higher
Share Market News
Here's why these 3 ASX shares are trading higher today
Share Market News
Why the Resonance Health share price is rocketing 20% higher
⏸️ Investing
The WORST investing mistake I've made recently
RHT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Resonance Health Ltd
Resonance Health Ltd is a healthcare company specializing in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its product includes FerriScan, a non-invasive liver diagnostic technology used for the measurement of iron in the liver, and HepaFat-Scan. The company's operating segment includes Services; Research and Development and Corporate. It generates maximum revenue from the Services segment. Geographically, it derives a majority of its revenue from North America and Europe-Middle-East-Africa (EMEA) and also has a presence in Asia/Pacific.
RHT Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 16 Apr 2024 | $0.08 | $0.00 | 0.00% | 109,922 | $0.08 | $0.08 | $0.08 |
| 15 Apr 2024 | $0.08 | $-0.01 | -12.50% | 6,250 | $0.08 | $0.08 | $0.08 |
| 12 Apr 2024 | $0.08 | $0.01 | 13.33% | 739,497 | $0.08 | $0.08 | $0.08 |
| 10 Apr 2024 | $0.08 | $0.00 | 0.00% | 118,800 | $0.08 | $0.08 | $0.08 |
| 09 Apr 2024 | $0.07 | $0.00 | 0.00% | 597,251 | $0.07 | $0.08 | $0.07 |
| 08 Apr 2024 | $0.07 | $0.00 | 0.00% | 3,080,069 | $0.07 | $0.09 | $0.06 |
| 05 Apr 2024 | $0.07 | $0.00 | 0.00% | 155,762 | $0.07 | $0.07 | $0.07 |
| 03 Apr 2024 | $0.07 | $-0.01 | -13.16% | 53,539 | $0.07 | $0.07 | $0.07 |
| 02 Apr 2024 | $0.08 | $0.01 | 14.29% | 807,375 | $0.07 | $0.08 | $0.07 |
| 28 Mar 2024 | $0.07 | $0.01 | 15.38% | 213,827 | $0.07 | $0.07 | $0.07 |
| 25 Mar 2024 | $0.07 | $-0.01 | -14.29% | 143,036 | $0.07 | $0.07 | $0.07 |
| 22 Mar 2024 | $0.07 | $0.01 | 15.87% | 95,762 | $0.06 | $0.07 | $0.06 |
| 21 Mar 2024 | $0.06 | $0.00 | 0.00% | 402 | $0.06 | $0.06 | $0.06 |
| 20 Mar 2024 | $0.06 | $-0.01 | -14.29% | 15,471 | $0.06 | $0.06 | $0.06 |
| 19 Mar 2024 | $0.07 | $0.00 | 0.00% | 67,930 | $0.07 | $0.07 | $0.07 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 08 Apr 2024 | Simon Panton | Buy | 500,000 | $32,500 |
On-market trade.
|
| 20 Mar 2024 | Simon Panton | Buy | 500,000 | $23,000 |
On-market trade.
|
| 20 Mar 2024 | Simon Panton | Transfer | 73,300,000 | $4,617,900 |
Off-market transfer. Assuming off market transfer of shres
|
| 20 Mar 2024 | Simon Panton | Transfer | 73,300,000 | $4,617,900 |
Off-market transfer. Assuming off market transfer of shares
|
| 20 Oct 2023 | Mitchell Wells | Buy | 610,000 | $36,600 |
Conversion of securities. As per announcement on 20-10-2023
|
| 20 Oct 2023 | Mitchell Wells | Exercise | 610,000 | $36,600 |
Conversion of securities. 1,220,000 unquoted Performance Rights, As per announcement on 20-10-2023
|
| 27 Sep 2023 | Travis Baroni | Buy | 610,000 | $44,622 |
On-market trade. average price
|
| 05 Sep 2023 | Aaron Brinkworth | Buy | 300,000 | $19,676 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Martin Peter Blake | Non-Executive DirectorNon-Executive Chairman | Oct 2007 |
Dr Blake is a Radiologist and Nuclear Physician and brings significant technical and industry experience to Resonance Health. Dr Blake received FAANMS as a post nominal in recognition of his Nuclear Medicine Specialist training undertaken in 1994 & 1995. He has been a Partner of Perth Radiological Clinic since 1997 and is currently on the Board of that Company. He is a member of Risk committee.
|
| Mr Mitchell MacDonald Wells | Company SecretaryNon Executive Director | Jun 2023 |
Mr Wells is an experienced senior executive and a qualified lawyer with commercial and legal experience in Australia, the United States of America and the United Kingdom. He has served as a Director and worked as a senior executive of public and private companies including ASX and US Nasdaq listed public companies. He recently served as Chair of two large non-profit organisations and he has previously served as the company secretary of two ASX listed public companies and as the corporate secretary of a US Nasdaq listed public company. He currently serves as a director of several private companies.
|
| Mr Simon Panton | Non-Executive Director | Oct 2009 |
Mr Panton has been a strong supporter of the Company and the FerriScan technology over a number of years and is a major shareholder of Resonance Health. Mr Panton brings skills in business and marketing having run his own successful business. He is a member of Risk committee.
|
| Dr Travis Baroni | Non-Executive Director | Nov 2016 |
Mr Baroni has broad experience across industrial research, commercialisation of technology, asset valuations and investment banking services. He has managed innovation development and technology strategy in a large company setting as well as being an active investor in early stage investments. He has worked in investment banking, providing advisory services to equity capital market transactions, corporate research and valuations to clients. He is the chair of Risk committee.
|
| Mr Aaron Brinkworth | Non-Executive Director | Mar 2023 |
Mr Brinkworth had a 22-year career with US headquartered, Nasdaq listed, Gilead Sciences, Inc. (Nasdaq: GILD). Mr Brinkworth held several commercial, licensing, and patient access roles, including that of Executive Director - Gilead Sciences Global Patient Solutions. He has served on the Board of Directors of the Royal Surf Lifesaving Society of Western Australia since 2020.
|
| Mr Andrew Duncan Harrison | Chief Executive Officer | Jul 2023 |
-
|
| Andrew Duncan Harrison | Chief Executive Officer |
-
|
|
| Ms Liesl Ellies | Joint Company secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Southam Investments 2003 Pty Ltd <Warwickshire Investment A/C> | 73,800,000 | 16.00% |
| HSBC Custody Nominees (Australia) Limited | 48,501,078 | 10.52% |
| Acuity Capital Investment Management Pty Ltd <Acuity Capital Holdings A/C> | 20,000,000 | 4.34% |
| Ms Alison Virginia Wesley <Wesley Family A/C> | 9,940,000 | 2.16% |
| Mr Paul John Van Dyk | 9,116,947 | 1.98% |
| Mr William Murray Thompson | 6,658,660 | 1.44% |
| Ms Jade Louise Thompson | 6,512,759 | 1.41% |
| Mr Bruce Alan Stevenson | 6,400,000 | 1.39% |
| Mr Helmut Rocker | 5,256,471 | 1.14% |
| Mr Paul Andrew Fitzmaurice & Mrs Tania Marie Fitzmaurice <Fitzmaurice Family S/F A/C> | 5,250,000 | 1.14% |
| Marcolongo Nominees Pty Ltd <Marcolongo Family A/C> | 5,186,200 | 1.12% |
| Dr Russell Kay Hancock | 4,610,000 | 1.00% |
| Mr Harish Garg | 4,501,245 | 0.98% |
| Mr Thomas Psarakis | 4,434,777 | 0.96% |
| Dr Martin Peter Blake | 3,798,590 | 0.82% |
| Morgan Stanley Australia Securities (Nominee) Pty Limited (No 1 Account) | 3,589,171 | 0.78% |
| Fullerton Private Capital Pty Limited | 3,500,000 | 0.76% |
| The University Of Western Australia | 3,478,750 | 0.75% |
| Neweconomy Com Au Nominees Pty Limited (900 Account) | 3,202,660 | 0.69% |
| Citicorp Nominees Pty Ltd | 2,574,632 | 0.56% |
